---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-026130"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:09:16.399134+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Verastem updates pipeline; PDUFA June 30, 2025 for avutometinib+defactinib in LGSOC

## Summary
- PDUFA action date June 30, 2025 for NDA of avutometinib+defactinib in KRAS mutant recurrent LGSOC; launch prep underway.
- RAMP 201 data: 44% ORR in KRAS mt, 31% overall; median PFS 12.9 months; 82% of patients had tumor shrinkage.
- Confirmatory RAMP 301 Phase 3 enrollment on track for completion by end of 2025.
- Filed U.S. IND for VS-7375 (KRAS G12D inhibitor) in Q1 2025; Phase 1/2a initiation expected mid-2025.
- Plan to present RAMP 203 (NSCLC) and RAMP 205 (pancreatic) data at med meetings in H2 2025.

## SEC filing metadata
- accession: 0001104659-25-026130
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/0001104659-25-026130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-026130
- JSON: https://secwatch.observer/filing/0001104659-25-026130.json
- Plain text: https://secwatch.observer/filing/0001104659-25-026130.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.